Clinical trials: High Altitude Pulmonary Hypertension
Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension
A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies…
- Conditions
- Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension, Intrauterine Growth Restriction
- Trial name
- NCT07312227
- Where
- 2 sites in United States, Bolivia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
High Altitude Pulmonary Hypertension, Sleep Apnea
Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders
High altitude pulmonary hypertension, a form of altitude illness that occurs in long-term residents at altitudes >2500 m, is characterized by dyspnea, hypoxemia, impaired exercise performance and hypertension in the pulmonary…
- Trial name
- NCT01621061
- Where
- Kyrgyzstan
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis.
- Trial name
- HAPE (NCT06852924)
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Novlead Inc.
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance/reactance in patients with pulmonary…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, High Altitude Effects, High Altitude
- Trial name
- NCT07804576
- Testing
- Re-ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Healthy, Healthy Adult
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in healthy individuals, who live…
- Conditions
- Healthy, Healthy Adult, High Altitude Effects, High Altitude
- Trial name
- NCT07801846
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Hypoxia-Induced Pulmonary Artery Hypertension
Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia
Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of the factors implicated in high-altitude pulmonary oedema.
- Trial name
- NCT00260819
- Testing
- Bosentan, Bosentam TRACLEER
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
High Altitude, Healthy
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy…
- Conditions
- High Altitude, Healthy, Healthy Adult, High Altitude Effects
- Trial name
- NCT07804589
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
High Altitude Polycythemia
Treatment of High Altitude Polycythemia by Acetazolamide
The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and 15% in the high altitude regions of South America. There is no pharmacological treatment available.
- Trial name
- NCT00424970
- Testing
- acetazolamide
- Where
- Peru
- Volunteers
- 55 people
- Sponsor
- Association pour la Recherche en Physiologie de l'Environnement
High Altitude Pulmonary Hypertension, Sleep Apnea
Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study.
- Trial name
- NCT03165019
- Where
- Kyrgyzstan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Excposure of High Altitude on ECG and Non-invasive Blood Pressure.
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response of High Altitude (Säntis, 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by…
- Trial name
- NCT03593083
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea Level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers
This is a Phase I, three period, two sequence, open-label, randomized, crossover study, with the primary objective of testing the safety and tolerability of combined oral doses of aminophylline and ambrisentan in healthy human…
- Trial name
- GQ01 (NCT01530464)
- Testing
- Aminophylline, Ambrisentan, Aminophylline plus ambrisentan
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Thies Schroeder
High Altitude Pulmonary Hypertension
Exercise Endurance Time on the 2nd Day at 2500 m High Altitude
The impact of a sojourn at 2500 m of high altitude for 26-30 h on constant work-rate exercise test time in patients with precapillary pulmonary hypertension
- Trial name
- NCT05131737
- Testing
- High altitude exposure, Low altitude exposure
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Altitude, Pulmonary Hypertension
Effect of Bosentan on Exercise Capacity at High Altitude
This study is to determine whether bosentan will alter exercise capacity after rapid ascent to high altitude. We hypothesize that bosentan administration will improve arterial oxygenation and exercise capacity.
- Trial name
- NCT00432978
- Testing
- Bosentan administration
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VA Loma Linda Health Care System
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on 6-minute walk distance (6MWD) assessed at 3200m.
- Trial name
- NCT06489743
- Testing
- 6-minute walk test (6MWT)
- Where
- Kyrgyzstan
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Oxygen Therapy
Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m
To study whether oxygen therapy titrated to maintain oxygenation (SpO2) > 90% at 2500m would resolve altitude-related adverse health effects, symptoms and impaired exercise during 30h exposure to high altitude.
- Trial name
- NCT05112172
- Testing
- Oxygen Therapy
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude ("Säntis"; 2500m above sea level) on pulmonary artery pressure and right heart function (echo)
- Trial name
- NCT03637166
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension
Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live >2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.
- Trial name
- NCT06489756
- Testing
- Echocardiography
- Where
- Kyrgyzstan
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06092424
- Testing
- Relocation from HA to LA
- Where
- Switzerland
- Volunteers
- 36 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure to High Altitude on Symptoms
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) in altitude related symptoms
- Trial name
- NCT03593005
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich